Global Pharmaceutical Excipients Market By Product Type (Inorganic Chemical, Organic Chemicals), By Formulation Type (Capsules Formulation, Tablets Formulation, Liquid Formulation), By Functionality Type (Fillers & Diluents, Suspending and Viscosity Agent, Binders) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast; 2023-2032

Report Overview

The global pharmaceutical excipients market size is expected to be worth around USD 11.8 bn by 2032 from USD 6.6 bn in 2022, growing at a CAGR of 5.8% during the forecast period from 2022 to 2032.

Pharmaceutical excipients are included in a dosage form, not for direct curative action but to help manufacture, support, protect, and enhance stability or bioavailability.

The inactive substances in pharmaceuticals, called excipients, are important product components that ease the process to promote solubility, drug delivery, pharmaceutical ingredients into the form of usable dosage, and betterment of taste.

Oral drugs’ popularity has been heavily increasing in recent years because the patient wants no pain, and it has a comparatively straightforward method, so end-users prefer this solution.

Due to the patient-oriented industry, hard-to-take, hard-solid tablets are replaced by innovative drugs such as ODG, chewable tablets, lozenges, and effervescent tablets.

Key Takeaway

• The global pharmaceutical excipients market is expected to reach approximately USD 11.8 billion by 2032.
• In 2022, the market had reached USD 6.6 billion, suggesting an immense potential of expansion.
• This expansion should be propelled by an estimated compound annual growth rate (CAGR) from 2022-2032 of 5.8%.
• By product type, in 2022, the Pharmaceutical Excipients market was dominated by the organic chemicals segment due to their non-toxic nature and efficiency.
• By formulation type, the oral formulations segment dominated the market share due to its enormous advantages and efficiency in dominating diseases.
• By functionality type, the fillers and diluents hold the largest market share owing to their use in the formulation of tablets and capsules
• In 2022, Europe dominated the market with the highest revenue share of over 38%.
• APAC is expected to grow at a higher pace among all the regions covered in the report.

Product Type Analysis

The Organic Chemicals Segment Dominated Largest Market Share in Product Type Owing To Their Non-Toxic Nature And Efficiency

The pharmaceutical excipients market is segmented on product types into inorganic and organic chemicals. Among these products, organic chemicals have the largest market share in pharmaceutical excipients. Organic chemicals are divided into further segments such as Proteins, carbohydrates, petrochemicals, oleo chemicals, and others.

Because organic chemicals will boost chemical use in a large portion of pharmaceutical formulations, which will help grow overall market sales. Drug manufacturers prefer organic chemicals due to their non-toxic nature and efficiency.

Formulation Type Analysis

The Oral Formulations Segment Dominated the Largest Market Share in Formulation Type Owing To Their Enormous Advantages And Efficiency In Dominating Diseases

Based on formulation types, the pharmaceutical excipients market is segmented into capsules, tablets, liquid, topical, parenteral, oral, and other formulations.

Among these formulations, the oral formulations segment has the largest share in the pharmaceutical excipients market due to its enormous advantages and efficiency in dominating diseases. In COVID-19, healthcare experts claimed that antiviral drugs are essential.

Hence, these drugs were in high demand during the pandemic. Tablet forms are developed for an oral dosage to increase efficiency against diseases like pneumonia. Tablet formulations for oral use are becoming more famous due to less intrusive consumption, which increases overall market growth.

Functionality Type Analysis

The Fillers And Diluents Segment Accounted for the Largest Market Share in Functionality Type Owing To Their Major Application In the Formulation Of Medicines

Based on functionality types, the pharmaceutical excipients market is segmented into fillers & diluents, suspending and viscosity agents, binders, flavoring agents and sweeteners, preservatives, coating agents, disintegrates, colorants, emulsifying agents, lubricants & glidants, disintegrates and, others functionality.

Among these functionalities, the largest market share was occupied by fillers and diluents. Because these are used in the formulation of tablets and capsules.

Key Market Segments

By Product Type

• Inorganic Chemical
• Organic Chemicals

By Formulation Type

• Capsules Formulation
• Tablets Formulation
• Liquid Formulation
• Parenteral Formulation
• Oral Formulation
• Other Formulations

By Functionality Type

• Fillers & Diluents
• Suspending and Viscosity Agent
• Binders
• Flavoring Agents and Sweeteners
• Preservatives
• Coating Agents
• Other Functionality Types

Drivers

Market Drivers Are Expanding the Market of Generics 

Generic drugs have the same effect as branded drugs; additionally, the safety guarantee provided by the brand can help increase customers’ trust in the brand. Pharmaceutical excipients market growth is increasing due to less price of generics.

The US healthcare system has saved up to 1.7 trillion by using generic drugs in the last ten years. Due to such advantages, countries provide and promote generic medicines.

The report of the Association for Accessible Medicines has shown that 90% of US prescriptions are generic drugs. From 2019 to 2022, many players, such as Eli Lilly, Bristol Myers Squibb, Novartis, and Merck, lose patents for 47 types of drugs.

The sheer volume of cheaper generic drugs will complete ongoing market demand at low cost, which is advantageous for generic drugs. Late-stage development problems can incur high charges, increase development costs, and affect overall profit margins.

As safety regulations increase, pharmaceutical companies must upgrade their current manufacturing with increasing production costs.

Restraints

High Cost and Time-Consuming Drug Development

By CBRA, the new drug manufacturing process took 10 to 12 years of hard work to convert the drug from the research lab to the patient. It takes 5-6 years for toxicology studies only for a particular drug by an industry expert; out of 10,000 drugs, only 10 drugs will go for pre-clinical tests. Of these, only 2 will go for human testing to get the drug’s approval.

There has been high development of biologic production in some previous years, and as such high initial investments are getting during the forecast period.

Opportunity

Multiple Functions Provided Tablets

Developments with high cost are helping excipient manufacturers to be capable of multiple functional excipients to compete with the ongoing pharmaceutical industry market.

Various functions of drugs can improve the manufacturing process with advantages such as reduced cost, decreased production time, increased efficiency, ODT formation, and developed chemical formation.

Market players can improve into a new version of present excipients by targeting specific application-based development and optimization, such as controlled release tablets.

Challenges

Regulating Quality and Standards

Even if there is an increased demand for pharmaceuticals, issues such as regulating the quality and basic standards demanded from users, patients, and makers can be detrimental to the overall performance increase in the company. With each supplier’s variation in excipients, there is an impact on the overall market growth.

Outsourcing Reducing Quality and Transparency in Supply Chain

Large manufacturing of excipients is outsourced to other manufacturers for underdeveloped countries. Hence, less control over the process indirectly reduces quality and transparency in the supply chain of underdeveloped countries.

Regional Analysis

Europe Has Dominated the Global Pharmaceutical Excipients Market Share Owing To Growing Healthcare Industry In the Region

Europe dominated the pharmaceutical excipients market with a 38% market share in 2022. Government schemes are used to decrease drug prices, increase investments in biologics discoveries, and develop dosage forms.

As demand for excipients that are newly formed increases, then the contribution to the overall growth of pharmaceuticals increases in the Europe market healthcare industry.

The Asia-Pacific region will increase its market share at a high rate in the forecast period as growth factors such as the low price of raw materials and the presence of a low-cost workforce in the region can help to grow the pharmaceutical excipients market. Countries such as India and China present massive market growth opportunities in the forecast period.

Key Regions

North America

• The US
• Canada
• Mexico

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Market Players Analysis

Significant key players have market presence in major countries such as the United States (Ashland Global Holdings, Inc., International Flavors & Fragrances, Inc., FMC corporation), Germany (BASF SE, Evonik Industries AG), France (Roquette Freres), etc., are responsible for the majority of market share.

Market Key Players

• Ashland Global Holdings
• BASF SE
• DuPont
• Roquette Feres
• Evonik Industries AG
• Associated British Foods
• Archer Daniels Midland Company
• Lubrizol Corporation
• Kerry Group
• Croda International PLC
• Roquette Frères
• FMC Corporation
• Other Key Players

Recent Market Developments

• In 2022, Less bio-availability, a long-time problem, can be solved using CD formulation in ongoing clinical trials by increasing bio-availability excipients.
• In 2022, Kerry Group Plc., a superior nutrition and taste company, has most extensive growth acquired two leading biotechnology companies, c-LEcta, an innovation in a biotechnology company, and Enmex, an enzyme manufacturer.
• In 2022, klucel xtend HPC company manufacturing drugs with new technological advancements like matrix polymer.
• In 2022, the Use of twin-screw melt granulation for hydroxypropyl cellulose and
• In 2021, the Product launching of BioHale solved the global supply problem by DFE Pharma.
• In 2020, Colorcon launched the Acryl-EZE II film coating line, which extends the pH range.

Report Scope